How should alendronate be prescribed, including dose, administration instructions, and necessary precautions?

How to Order Alendronate

Alendronate should be prescribed as 70 mg once weekly for treatment of osteoporosis or 35 mg once weekly for prevention in postmenopausal women, taken after an overnight fast with a full glass of plain water, at least 30 minutes before any food, beverage, or other medication, with the patient remaining upright for at least 30 minutes. 1, 2

Dosing Regimens

The most commonly used formulations are 1, 2:

For Treatment:

• 70 mg once weekly (preferred for convenience and adherence)
• 10 mg once daily (alternative)

For Prevention:

• 35 mg once weekly (preferred)
• 5 mg once daily (alternative)

Special Populations:

• Glucocorticoid-induced osteoporosis: 5 mg daily (10 mg daily for postmenopausal women not on estrogen) 2
• Men with osteoporosis: 70 mg weekly or 10 mg daily 2
• Paget's disease: 40 mg daily for 6 months 2

The weekly formulation is strongly preferred because compliance with daily bisphosphonates is poor (~30% still continuing at 1 year), and weekly dosing provides therapeutically equivalent outcomes while improving adherence 3, 4.

Critical Administration Instructions

These instructions are non-negotiable and must be emphasized to patients, as failure to follow them increases risk of esophageal complications 1, 5:

1. Timing: Take immediately upon arising for the day, after overnight fast
2. Fluid: Swallow with full glass (6-8 oz) of plain water only—no other beverages
3. Waiting period: Remain upright (sitting or standing) for at least 30 minutes
4. Food/medication delay: Take nothing else by mouth for at least 30 minutes after the dose
5. Never at bedtime: Do not take at bedtime or before arising

Even orange juice or coffee markedly reduces absorption 2. Taking with food or waiting less than 30 minutes substantially decreases effectiveness 1, 2.

Pre-Treatment Requirements

Before initiating alendronate 1, 6, 5:

• Correct hypocalcemia (absolute contraindication) 1, 2
• Correct vitamin D deficiency (especially before IV bisphosphonates, as deficiency increases hypocalcemia risk) 6, 5
• Ensure adequate calcium/vitamin D supplementation: 1200 mg calcium and 800-1000 IU vitamin D daily 6
• Check renal function: Contraindicated if GFR <35 mL/min for alendronate 1
• Complete necessary dental work before starting therapy (allow healing time) 5

Absolute Contraindications

1, 2:

• Hypocalcemia
• Esophageal abnormalities (achalasia, stricture, dysmotility)
• Inability to stand or sit upright for at least 30 minutes
• Inability to follow dosing instructions
• GFR <35 mL/min
• Drug hypersensitivity

Relative Contraindications/Cautions

1, 6:

• Active esophageal disease
• GI malabsorption syndromes (gastric bypass, celiac disease, Crohn's disease)
• Patients at risk of aspiration (for solution formulation)

Missed Dose Instructions

If a weekly dose is missed 2:

• Take one dose the morning after remembering
• Do not take two doses on the same day
• Return to the original weekly schedule

Common Pitfalls to Avoid

1. Inadequate waiting time: Patients must wait full 30 minutes upright before eating—this is the most common error that reduces efficacy and increases esophageal risk 1, 2

2. Taking with wrong beverage: Only plain water—mineral water, coffee, juice all significantly reduce absorption 1, 2

3. Not correcting vitamin D deficiency first: This increases risk of bisphosphonate-related hypocalcemia, particularly with IV formulations 6, 5

4. Ignoring renal function: Alendronate should not be used with GFR <35 mL/min 1

5. Not counseling about esophageal symptoms: Patients must know to stop medication and contact physician if they develop difficulty swallowing, pain on swallowing, retrosternal pain, or new/worsening heartburn 2

Duration and Monitoring Considerations

After 5 years of oral bisphosphonate therapy, reassess fracture risk 3, 7:

• High-risk patients (hip T-score <-2.5, prior major fracture, or fracture on therapy): Continue up to 10 years with periodic evaluation
• Lower-risk patients (hip T-score >-2.0, no recent fractures): Consider drug holiday of 2-3 years

The risk of atypical femoral fractures increases with duration beyond 5 years, though remains rare and is outweighed by vertebral fracture reduction in high-risk patients 3, 7.

Alternative Formulations

For patients who cannot tolerate oral alendronate due to GI issues or inability to follow dosing instructions, consider 1:

• IV zoledronic acid (5 mg annually)
• Denosumab (60 mg subcutaneously every 6 months)

These alternatives avoid the strict oral administration requirements while maintaining fracture efficacy 1, 5.